BioHarvest Sciences Inc. (BHST)
(Delayed Data from NSDQ)
$8.71 USD
-0.30 (-3.28%)
Updated Sep 18, 2025 03:25 PM ET
After-Market: $8.80 +0.10 (1.09%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
BioHarvest Sciences Inc.'s return on equity, or ROE, is -11,357.84% compared to the ROE of the Medical - Biomedical and Genetics industry of -67.20%. While this shows that BHST has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
BHST 8.71 -0.30(-3.28%)
Will BHST be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BHST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BHST
BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Misses Revenue Estimates
The Joint Corp. (JYNT) Reports Q2 Loss, Tops Revenue Estimates
BHST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue Estimates
BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains?
What Makes BioHarvest Sciences Inc. (BHST) a Good Fit for 'Trend Investing'
Other News for BHST
BHST forms Calm After Storm on September 17
BHST forms MACD Bullish Centerline Cross on September 16
Is BHST poised for gains? MACD Bullish Signal Line Cross shows up after advancing 3.08%
BHST Crossed Above 20 Day Moving Average on September 12
The technical outlook for BHST is unchanged after it falls 0.93% on September 11